PDSB shares are up 163.64% during regular trading on Monday, climbing from $0.22 at the previous close to $0.58 per share, as of the latest session price. The clinical-stage biopharmaceutical company announced a financing deal worth up to $22.55 million led by Dr. Patrick Soon-Shiong, founder of NantWorks.
Financing Led by Biotech Billionaire Dr. Patrick Soon-Shiong
The primary catalyst for PDSB sharp move higher is the financing announcement made public on September 8, 2026, via GlobeNewswire. PDS Biotech disclosed up to $22.55 million in financing, with the round led by Dr. Patrick Soon-Shiong, a prominent figure in the biotech and oncology space through his company NantWorks.
Dr. Soon-Shiong brings significant credibility and financial firepower to the small-cap biotech. His involvement as the lead investor signals institutional confidence in PDS Biotech pipeline, particularly its lead candidate PDS0101, which is advancing through Phase III trials for HPV-associated cancers including head and neck cancer and cervical cancer.
Trading Volume Spikes to 141 Million Shares
Trading activity in PDSB has been extraordinary. Volume reached 141,577,419 shares during the session, compared to the average daily volume of approximately 4.3 million shares over the short interest period. This represents roughly 33 times the typical daily trading activity.
The stock opened at $0.49 before accelerating to the session high of $0.58, representing the full-day move occurring during regular market hours. The short interest of 1,894,222 shares and days-to-cover ratio of 1.00 suggest the float can absorb significant volume, though the outsized move raises questions about liquidity and potential short covering pressure.
What PDS Biotech Does
PDS Biotechnology focuses on developing multifunctional cancer immunotherapies. The companys lead product candidate PDS0101 targets HPV16-associated malignancies and is currently in a Phase III clinical trial called VERSATILE-003. The FDA has aligned with the company on using progression-free survival as the primary endpoint, which could support an accelerated approval pathway.
Beyond PDS0101, PDS Biotech is developing PDS01ADC, an IL-12 tumor-targeted immunocytokine, which recently showed positive interim Phase 2 data in metastatic colorectal cancer and third-line metastatic castration-resistant prostate cancer in trials led by the National Cancer Institute.
Small-Cap Biotech Financing Context
Biotech companies frequently turn to equity financings to fund expensive clinical trials. For small-cap companies like PDSB with a market capitalization around $32 million and only 24 employees, securing capital from high-profile investors is critical. Dr. Soon-Shiong involvement may signal plans for collaboration or a longer-term investment thesis beyond simply providing liquidity.
The financing amount of up to $22.55 million represents roughly 70% of PDSB current market cap, indicating a meaningful capital raise relative to the companys existing equity value.
Outlook
Investors should monitor whether additional details emerge about the financing terms, including the specific structure of the deal and any associated warrants or conversion features. The dramatic price increase means the stock now trades at a significant premium to recent historical levels, and future capital raises, if needed, would occur at higher share counts or lower prices.
PDS Biotech next scheduled corporate update may come through a formal 8-K filing with the SEC, which will provide full terms of the financing arrangement.
Note: No chart data is available for this session.